Letters to the Editor
Vol. 88 No. 1 (2016)
https://doi.org/10.4081/aiua.2016.1.72
Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 25 January 2016
Published: 31 March 2016
Published: 31 March 2016
2665
Views
1345
Downloads
Downloads
Download data is not yet available.
Supporting Agencies
The TROPIC study was sponsored by Sanofi. Editorial support in the preparation of this letter was provided by Danielle Lindley of MediTech Media funded by Sanofi.
How to Cite
Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. (2016). Archivio Italiano Di Urologia E Andrologia, 88(1), 72-73. https://doi.org/10.4081/aiua.2016.1.72
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.